Bloomberg News

Protalix Falls Most in 9 Months on FDA Protein Delay

December 06, 2011

(Corrects size of drop in lead, second paragraph.)

Dec. 6 (Bloomberg) -- Protalix BioTherapeutics Inc. fell the most in more than nine months after the biotechnology company said the U.S. Food and Drug Administration delayed a decision on its Gaucher disease protein.

The shares tumbled 21 percent, the most since Feb. 27, to 18.30 shekels at 3:43 p.m. in Tel Aviv.

Global market map: MMAP <GO> Most active stocks: MOST <GO> Global stocks stories: TOP STK <GO> Most read stock market stories: MNI STK <GO> Israel Daybook: NI ISRAELDAY <GO> Top Israel stories: TOP ISRAEL <GO>

--Editors: Claudia Maedler, Shaji Mathew

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus